Keyphrases
Survival Prediction
100%
Pancreatic Cancer
100%
Cancer Patients
100%
Gemcitabine
100%
Antitrypsin
100%
Resectable Pancreatic Cancer
75%
Gemcitabine Monotherapy
75%
Antichymotrypsin
50%
Patient Survival
25%
Confidence Interval
25%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
25%
Large Cohort
25%
Clinical High Risk
25%
Overall Survival
25%
Statistical Significance
25%
Patient Outcomes
25%
Alkaline Phosphatase
25%
Nomogram
25%
Scoring System
25%
Log-rank Test
25%
Biomarker Candidates
25%
Median Survival Time
25%
2-cycles
25%
Performance Status
25%
New Biomarkers
25%
Bootstrap
25%
Multivariate Cox Regression Analysis
25%
Overall Survival of Patients
25%
Concordance Index
25%
Reverse Phase Protein Array
25%
Leukocyte Count
25%
Plasma Proteomics
25%
External Validation Study
25%
Welch's T-test
25%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Gemcitabine
100%
Trypsin Inhibitor
100%
Survival Prediction
100%
Monotherapy
75%
Biological Marker
75%
Overall Survival
50%
Chymotrypsin Inhibitor
50%
Base
25%
Alkaline Phosphatase
25%
Median Survival Time
25%
Protein Microarray
25%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Survival Prediction
100%
Overall Survival
50%
Alkaline Phosphatase
25%
Median Survival Time
25%
Leukocyte Count
25%
Proteome
25%
Liquid Chromatography-Mass Spectrometry
25%
Protein Microarray
25%